AMYPAD - Amyloid imaging to prevent Alzheimer’s disease
A common sign of Alzheimer’s disease are deposits of a protein called beta amyloid. The AMYPAD project studies the value of using an imaging technique called positron emission tomography (PET) to scan people’s brains for these beta amyloid deposits. AMYPAD will carry out beta-amyloid PET imaging on a large number of people who are suspected to be in the early stages of Alzheimer’s disease. The goal is to determine the clinical added value of PET imaging in diagnosis and patient monitoring.
AMYPAD will work closely with the Innovative Medicines Initiative’s EPAD project, which is working to increase our understanding of the early stages of dementia and to create a platform to test treatments designed to prevent dementia.
Gill Farrar (GE Healthcare) is AMYPAD representative on Neuronet's Scientific Coordination Board.
Twitter handle: @IMI_AMYPAD
Read the latest AMYPAD newsletter (November 2021) here.
EPAD - European prevention of Alzheimer’s dementia consortium
Today, research increasingly focuses on ways to prevent the onset of Alzheimer’s dementia in the first place. The EPAD project is pioneering a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s disease dementia. Using an adaptive trial design should deliver better results faster and at lower cost.
A key project outcome is the open access EPAD database, publicly available to the research community. To access the data, you will need to make an online request via EPAD LCS Research Access Process. To find how to apply and learn what data is available in the EPAD data releases before your apply, visit the EPAD website here.
Although the funding period of EPAD ended in October 2020, local actions are taking place to keep the EPAD Longitudinal Cohort data collection going.
Find out more about the project by watching this video:
Craig Ritchie (University of Edinburgh) is EPAD representative on Neuronet's Scientific Coordination Board.
Twitter handle: @IMI_EPAD
Read the latest EPAD newsletter (July 2020) here.
EPND - The European Platform for Neurodegenerative Diseases
EPND integrates existing initiatives to build, grow, and deliver a scalable and self-sustainable platform for storage and analysis of high-quality clinical samples and data collections. It is a public-private partnership funded by the Innovative Medicines Initiative (IMI), aiming to become a future European infrastructure, facilitating access to biological samples and data to accelerate biomarker discovery and validation and eventually support the development of therapeutics for neurodegenerative diseases.
Raj Long (Bill & Melinda Gates Foundation) is EPND representative on Neuronet's Scientific Coordination Board.
Twitter handle: @IMI_EPND
IDEA-FAST - Identifying Digital Endpoints to Assess Fatigue, Sleep and Activities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases
Fatigue and sleep disturbances are common symptoms of many chronic diseases, and are associated with a poor quality of life and greater healthcare costs. Today, efforts to measure these symptoms, e.g. in clinical trials, are based largely on standardised paper questionnaires, which do not give very reliable results.
IDEA-FAST aims to identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily life (ADL), disability and health-related quality of life (HRQoL) for the following neurodegenerative diseases (NDD): Parkinson’s Disease (PD), Huntington’s Disease (HD) and the following immune-mediated inflammatory diseases (IMID): Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Primary Sjögren’s Syndrome (PSS), and Inflammatory Bowel Disease (IBD).
Walter Maetzler (University Of Kiel) is IDEA-FAST representative on Neuronet's Scientific Coordination Board.
Twitter handle: @ideafastproject
Read the latest IDEA-FAST newsletter (April 2020) here.
IM2PACT - Investigating mechanisms and models predictive of accessibility of therapeutics into the brain
As the name suggests, the blood-brain barrier (BBB) tightly controls access to our brains, allowing nutrients and essential substances through, but blocking pathogens, for example. Getting medicines through this protective shield is a major challenge for drug developers, particularly those developing biopharmaceuticals, which are based on large molecules like proteins and antibodies. The goal of IM2PACT is to advance our understanding of the BBB to facilitate the development of more effective treatments for a range of neurological and metabolic disorders.
Specifically, the project aims to develop better models of the BBB so that researchers can study it more easily; investigate the biology of the BBB in both health and disease, and the transport routes across it; and to develop innovative systems capable of delivering medicines to the brain. The project will focus on two major disease areas: neurodegenerative diseases, including Alzheimer and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease and motor neurone disease), vascular dementia, and multiple sclerosis; and metabolism-related diseases (mainly diabetes and obesity).
Dominique Lesuisse (Sanofi) is IM2PACT representative on Neuronet's Scientific Coordination Board.
Twitter handle: @im2pact_project
IMPRiND - Inhibiting misfolded protein propagation in neurodegenerative diseases
Alzheimer’s and Parkinson’s diseases are characterised by the progressive loss of brain cells. Research suggests that this loss may be due to brain cells that release but also uptake misfolded proteins that clump together. This in turn might lead to an ongoing spreading of the death of brain cells.
If these processes could be blocked, disease progression could be halted. However, the forces driving these processes are currently poorly understood. The IMPRiND project is working to shed further light into this area and aims to understand how these proteins are handled once inside brain cells and how they are moved from cell to cell.
To do this, the project team works together to develop standardised tools and tests to establish disease-relevant mechanisms that could be targeted by drugs in the future.
George Tofaris (University of Oxford) is IMPRiND representative on Neuronet's Scientific Coordination Board.
Twitter handle: @imprind
Mobilise-D - Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
Mobilise-D will develop a comprehensive system to monitor and evaluate people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.
The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care.
Have a look at the Mobilise-D public information sheet to gain a high-level & easy to understand overview of the project.
Lynn Rochester (Newcastle University) is Mobilise-D representative on Neuronet's Scientific Coordination Board.
Twitter handle: @Mobilise_D
Read the latest Mobilise-D newsletter (January 2022) here.
PD-MIND – Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
Currently there is an unmet clinical need to treat Parkinson Disease with Mild Cognitive Impairment (PD-MCI). In fact, nicotinic agonists are specifically relevant for this condition.
Hence, the major aim of the project PD-MIND (Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug) is to identify the potential of the nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, parallel group, international multicentre study on cognitive function in people diagnosed with PD-MCI.
Dag Aarsland (King’s College London) is PD-MIND representative on Neuronet’s Scientific Coordination Board.
PD-MitoQUANT - A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:
- improve our understanding of mitochondrial dysfunction in Parkinson’s,
- identify and validate molecular drivers and mechanisms in Parkinson’s, and
- discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.
Jochen Prehn (Royal College of Surgeons in Ireland) is PD-MitoQUANT representative on Neuronet's Scientific Coordination Board.
PHAGO - Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
Alzheimer’s disease is an age-related chronic neurodegenerative disease with progressive loss of nerve cells and their connectivity in the brain. People affected experience memory loss and progressive dementia. Recent research has shown that two genes involved in the innate immune system, TREM2 and CD33, are associated with Alzheimer’s disease and could therefore be potential targets for drug development.
However, their exact role in the progression of the disease is still poorly understood. The PHAGO project aims to develop tools and methods to study the function of these genes and to identify druggable points for intervention. The project results will therefore pave the way for the development of novel drugs that could tackle Alzheimer’s disease via this route.
Have a look at the PHAGO flyer here to gain a high-level overview of the project.
Andreas Ebneth (Janssen Pharmaceutica NV) is PHAGO representative on Neuronet's Scientific Coordination Board.
Twitter handle: @phago_imi
PRISM2 - Psychiatric ratings using intermediate stratified markers 2
IMI’s PRISM project focused on social dysfunction, a common early symptom of many neurological disorders. PRISM shed new light on the underlying causes of social dysfunction in schizophrenia and Alzheimer’s disease, including some of the genes involved as well as a neural network.
Interestingly, the neural network involved in social dysfunction appears to be the same in both diseases. The team also developed an early version of a suite of tests, including scans, blood tests and smartphone monitoring, which could potentially make it easier to diagnose conditions, indicate the brain mechanisms involved, and identify targets for new treatments.
The goal of the PRISM 2 project is to build on the achievements of the original PRISM project. Specifically, it aims to validate PRISM’s findings on social dysfunction in schizophrenia and Alzheimer’s disease, and investigate whether they also apply to major depressive disorder.
Ultimately, the work of PRISM 2 should ensure that these findings will result in more accurate diagnoses and treatments for people with Alzheimer’s disease, schizophrenia and major depressive disorder.
Hugh Marston (Boehringer Ingelheim) is PRISM2 representative on Neuronet's Scientific Coordination Board.
Twitter handle: @IMI2PRISM2
RADAR-AD - Remote assessment of disease and relapse – Alzheimer’s disease
People in the earliest stages of Alzheimer’s disease experience declining cognitive and functional abilities, making it harder for them to remember things and places, carry out simple calculations, use a phone/computer, drive, and adhere to medications. The goal of the RADAR-AD consortium is to develop a digital platform that would draw on smartphone, wearable and home-based digital technologies to identify subtle changes in the cognitive and functional abilities of people living with Alzheimer’s disease.
The project will adapt the existing RADAR-CNS project’s platform and experiences for Alzheimer’s disease. Among other things, the team will have to take account of the fact that many people living with Alzheimer’s disease are older and so may be less familiar with technology, while their condition may make it more difficult for them to learn to handle technological devices. People with Alzheimer’s disease will be fundamentally involved in the design and development of the project so that the clinical tests and final outcomes put in place are acceptable and appropriate for them.
The platform will be tested in a clinical study of people with different stages of Alzheimer’s disease. Ultimately, the goal of the project is the development and validation of technology-enabled, quantitative and sensitive measures of functional decline in people with early stage AD.
Dag Aarsland (King's College London) is RADAR-AD representative on Neuronet's Scientific Coordination Board.
Twitter handle: @RADARAD7
Read the latest RADAR-AD newsletter (January 2022) here.
RADAR-CNS - Remote Assessment of Disease and Relapse in Central Nervous System Disorders
The RADAR-CNS project aims to develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis by using wearable devices and smartphone technology. The key goal of the project is to improve patients’ symptoms and quality of life and to change how these and other chronic disorders are treated.
People with epilepsy, multiple sclerosis and depression often experience periods in which their symptoms are manageable, followed by periods of deterioration and acute illness (relapse). Patient surveys have repeatedly highlighted the need to predict when relapses will happen and to improve the treatments available to stop them from occurring.
Continuous remote assessment using smartphones and wearable devices provides a complete picture of a patient’s condition at a level of detail which was previously unachievable. Moreover, it could potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient from relapsing or worsening before they even sought treatment.
Matthew Hotopf (King's College London) is RADAR-CNS representative on Neuronet's Scientific Coordination Board.
Twitter handle: @RADARCNS
Read the latest RADAR-AD newsletter (July 2021) here.